Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Revenue (2016 - 2025)

IGC Pharma (IGC) has disclosed Revenue for 16 consecutive years, with $191000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 53.64% to $191000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 6.51% decrease, with the full-year FY2025 number at $1.3 million, down 5.5% from a year prior.
  • Revenue was $191000.0 for Q3 2025 at IGC Pharma, down from $328000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $555000.0 in Q2 2023 to a low of $56000.0 in Q3 2021.
  • A 5-year average of $238157.9 and a median of $212000.0 in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 86.82% in 2021, then soared 260.71% in 2022.
  • IGC Pharma's Revenue stood at $142000.0 in 2021, then soared by 133.8% to $332000.0 in 2022, then plummeted by 38.55% to $204000.0 in 2023, then rose by 25.98% to $257000.0 in 2024, then dropped by 25.68% to $191000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Revenue are $191000.0 (Q3 2025), $328000.0 (Q2 2025), and $330000.0 (Q1 2025).